Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2008

Bristol-Myers Squibb Extends Research Collaboration with Exelixis

  • Exelixis will receive $6 million in additional funding with the one-year extension of its research collaboration with Bristol-Myers Squibb (BMS). The firms will now work together until January 12, 2010. The partnership focuses on therapies targeted against the Liver X Receptor, a nuclear hormone receptor implicated in cardiovascular and metabolic disorders.

    Under the terms of the original collaboration, the companies will identify drug candidates that are ready for IND-enabling studies. Bristol-Myers Squibb will undertake further preclinical and clinical development, regulatory activities, manufacturing, and sales/marketing operations for the compounds.

    The collaboration was established in January of 2006 for two years. Bristol-Myers Squibb previously extended the agreement through to January 12, 2009 in 2007.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »